Loading...
XNAS
SERA
Market cap115mUSD
Dec 05, Last price  
3.08USD
1D
3.36%
1Q
-7.78%
IPO
-72.00%
Name

Sera Prognostics Inc

Chart & Performance

D1W1MN
XNAS:SERA chart
P/E
P/S
1,505.08
EPS
Div Yield, %
Shrs. gr., 5y
1.55%
Rev. gr., 5y
16.42%
Revenues
77k
-74.84%
36,00025,00082,000268,000306,00077,000
Net income
-33m
L-9.23%
-20,439,000-21,607,000-36,228,000-44,247,000-36,242,000-32,898,000
CFO
-14m
L-47.81%
-19,324,000-16,868,000-31,636,000-34,610,000-27,188,000-14,189,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
IPO date
Jul 15, 2021
Employees
87
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT